Featured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, Yantai 264003, Shandong, PR China.
College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, Hebei, PR China.
Int J Biol Macromol. 2024 Feb;259(Pt 2):129352. doi: 10.1016/j.ijbiomac.2024.129352. Epub 2024 Jan 11.
Converting M2 macrophages into an M1 phenotype in the tumor microenvironment, provides a new direction for tumor treatment. Here, we further report CVPW-1, a new polysaccharide of 1.03 × 10 Da that was isolated from Coriolus versicolor. Its monosaccharide was composed of mannose, glucose, and galactose at a ratio of 1.00:8.73:1.68. The backbone of CVPW-1 was composed of (1 → 3)-linked α-D-Glcp residues and (1 → 3,6)-linked α-D-Glcp residues that branched at O-6. The branch consisted of (1 → 6)-linked α-D-Glcp residues and (1 → 4)-linked α-D-Glap, and some branches were terminated with (1→)-linked β-D-Manp residues according to the results of HPLC, FT-IR, GC-MS, 1D and 2D NMR. Meanwhile, CVPW-1 could polarize M2 macrophages to M1 phenotypein vitro by binding to TLR4 and inducing the activation of Akt, JNK and NF-κB. This process involved reversing the functional inhibition of CD8 T lymphocytes by inhibiting the expression of TREM2 in M2 macrophages. The in vivo experiments showed that oral administration of CVPW-1 could inhibit the growth of tumor in mice and polarize TAMs to M1 phenotype. Thus, the novel polysaccharide CVPW-1 from Coriolus versicolor might activate a variety of immune cells and then play an anti-tumor role. These results demonstrated that CVPW-1 could be developed as a potential immuno-oncology treatment reagent.
将 M2 巨噬细胞转化为肿瘤微环境中的 M1 表型,为肿瘤治疗提供了新的方向。在这里,我们进一步报道了一种新的多糖 CVPW-1,它是从云芝中分离得到的,分子量为 1.03×10 Da。其单糖由甘露糖、葡萄糖和半乳糖组成,摩尔比为 1.00:8.73:1.68。CVPW-1 的骨架由(1→3)-连接的α-D-Glcp 残基和(1→3,6)-连接的α-D-Glcp 残基组成,这些残基在 O-6 处分支。支链由(1→6)-连接的α-D-Glcp 残基和(1→4)-连接的α-D-Glap 残基组成,一些支链根据 HPLC、FT-IR、GC-MS、1D 和 2D NMR 的结果被(1→)-连接的β-D-Manp 残基所终止。同时,CVPW-1 可以通过与 TLR4 结合并诱导 Akt、JNK 和 NF-κB 的激活,将 M2 巨噬细胞体外极化为 M1 表型。这个过程涉及通过抑制 M2 巨噬细胞中 TREM2 的表达来逆转 CD8 T 淋巴细胞的功能抑制。体内实验表明,CVPW-1 的口服给药可以抑制小鼠肿瘤的生长,并将 TAMs 极化为 M1 表型。因此,来自云芝的新型多糖 CVPW-1 可能激活多种免疫细胞,从而发挥抗肿瘤作用。这些结果表明 CVPW-1 可以开发为一种有潜力的免疫肿瘤治疗试剂。